These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 10927799)
1. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Khoury SJ; Guttmann CR; Orav EJ; Kikinis R; Jolesz FA; Weiner HL Arch Neurol; 2000 Aug; 57(8):1183-9. PubMed ID: 10927799 [TBL] [Abstract][Full Text] [Related]
2. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. Weiner HL; Guttmann CR; Khoury SJ; Orav EJ; Hohol MJ; Kikinis R; Jolesz FA J Neuroimmunol; 2000 May; 104(2):164-73. PubMed ID: 10713356 [TBL] [Abstract][Full Text] [Related]
3. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. Zoukos Y; Thomaides TN; Kidd D; Cuzner ML; Thompson A J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):197-202. PubMed ID: 12531948 [TBL] [Abstract][Full Text] [Related]
4. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939 [TBL] [Abstract][Full Text] [Related]
5. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027 [TBL] [Abstract][Full Text] [Related]
6. A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. Constantinescu CS; Kamoun M; Dotti M; Farber RE; Galetta SL; Rostami A J Neurol Sci; 1995 Jun; 130(2):178-82. PubMed ID: 8586983 [TBL] [Abstract][Full Text] [Related]
7. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400 [TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. Ruiz-Peña JL; Piñero P; Sellers G; Argente J; Casado A; Foronda J; Uclés A; Izquierdo G BMC Neurol; 2004 Jun; 4():8. PubMed ID: 15191618 [TBL] [Abstract][Full Text] [Related]
10. Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis. Hintzen RQ; Pot K; Paty D; Oger J Acta Neurol Scand; 2000 Jan; 101(1):57-60. PubMed ID: 10660154 [TBL] [Abstract][Full Text] [Related]